Dr. Mitchell Shiffman, of the Liver Institute of Virginia, talks with Hepatology Digest at the American Association for the Study of Liver Diseases about the latest advances in curing hepatitis C, specifically about the role of peginterferon in the era of triple therapy for HCV.
More effective anti-viral agents and better forms of peginterferon have recently been developed for the treatment of chronic HCV. Two anti-viral medications, telaprevir and boceprevir, are in the final phases of development and testing in clinical trials. Although these medications are still considered experimental clinical studies have already demonstrated that these medications can increase the cure rate in patients with chronic HCV genotype 1 from 40 to nearly 70%. The majority of these patients require only 6 months of treatment.
Clinical trials utilizing many new medications for treating chronic HCV are being conducted by the Liver Institute of Virginia. Patients may be eligible for enrollment into a clinical trial after a complete evaluation by Dr. Shiffman. These clinical trials may offer patients a higher cure rate, be associated with less side effects during the treatment or both.
For more information about hepatitis C treatment, to learn more about the latest liver disease clinical trials in Newport News or Richmond, or to request an evaluation with Dr. Shiffman, please visit the Liver Institute of Virginia’s website at bshr.com/liver.